<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986970</url>
  </required_header>
  <id_info>
    <org_study_id>The CHAPS Trial</org_study_id>
    <nct_id>NCT03986970</nct_id>
  </id_info>
  <brief_title>The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention</brief_title>
  <acronym>CHAPS</acronym>
  <official_title>Combined HIV Adolescent PrEP and Prevention: On Demand Pre-exposure Prophylaxis to Provide Protection From HIV in Men - Using Foreskin Tissue to Estimate Protection (Phase II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatima Mayat</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MRC/UVRI Uganda Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wits Health Consortium (Pty) Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of different PrEP drugs (FTC-TDF and FTC-TAF), doses and timing of
      doses on p24 antigen level in resected foreskin tissue following HIV exposure ex vivo
      challenge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Investigate the timing and dose of FTC-TDF and FTC-TAF as oral PrEP and in vitro PEP
           (applied directly to removed foreskin tissue) required to prevent ex vivo HIV infection
           in foreskin tissue and blood using the explant model

        2. Determine blood, rectal fluid and foreskin tissue concentrations of FTC, TFV, TAF and
           their active metabolites that are required for ex vivo HIV protection

        3. Evaluate inflammation, cellular activation, foreskin mucosal integrity, gene expression
           and microbiome in foreskin tissue following oral in vivo PrEP and in vitro PEP

        4. Evaluate the efficacy of in vitro post exposure dosing with PrEP in protection against
           ex vivo HIV infection using the explant model

        5. To investigate sexual behaviour, PrEP acceptability and feedback on HIV prevention
           trials implementation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, randomised controlled trial (RCT)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Infection free</measure>
    <time_frame>15 days</time_frame>
    <description>We will ascertain the proportion of patients' foreskin tissue that is not infected with HIV 15 days following our ex-vivo HIV challenge. We will use the concentration of p24 antigen (pg/mL) at day15 and also report the slope of the p24 curves from day 3 to 15 (pg/mL per day) and also the AUC day 3 to 15 (pg/mL days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timing</measure>
    <time_frame>1 year</time_frame>
    <description>The delay between the timing of last dose of FTC-TDF and FTC-TAF as oral PrEP and the timing of circumcision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose</measure>
    <time_frame>1 year</time_frame>
    <description>The efficacy of preventing in-vitro HIV infection by dose of FTC-TDF and FTC-TAF as oral PrEP compared to no intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood PrEP Concentrations</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma concentrations (ng/mL) of FTC, TFV, TAF and their active metabolites that are required for ex vivo HIV protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rectal Fluid PrEP concentrations</measure>
    <time_frame>1 year</time_frame>
    <description>Rectal fluid concentrations (ng/mL) of FTC, TFV, TAF and their active metabolites that are required for ex vivo HIV protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foreskin tissue PrEP concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Foreskin tissue concentrations (ng/mL) of FTC, TFV, TAF and their active metabolites that are required for ex vivo HIV protection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of post-exposure PrEP</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of participants' foreskin tissue that remains HIV infection free in the ex-vivo challenge model when additional doses of PrEP are added to that model.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Arm 1: Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No PrEP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: FTC-TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC-TDF one day, 5 hours before circumcision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: FTC-TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC-TDF one day, 21 hours before circumcision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: FTC-TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC-TDF two days, 5 hours before circumcision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: FTC-TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC-TDF two days, 21 hours before circumcision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: FTC-TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC-TAF one day, 5 hours before circumcision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7: FTC-TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC-TAF one day, 21 hours before circumcision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8: FTC-TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC-TAF two days, 5 hours before circumcision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9: FTC-TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC-TAF two days, 21 hours before circumcision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Pre-exposure prophylaxis</description>
    <arm_group_label>Arm 2: FTC-TDF</arm_group_label>
    <arm_group_label>Arm 3: FTC-TDF</arm_group_label>
    <arm_group_label>Arm 4: FTC-TDF</arm_group_label>
    <arm_group_label>Arm 5: FTC-TDF</arm_group_label>
    <arm_group_label>Arm 6: FTC-TAF</arm_group_label>
    <arm_group_label>Arm 7: FTC-TAF</arm_group_label>
    <arm_group_label>Arm 8: FTC-TAF</arm_group_label>
    <arm_group_label>Arm 9: FTC-TAF</arm_group_label>
    <other_name>Emtricitabine, Tenofovir disoproxil, Tenofovir alafenamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must satisfy all the following criteria within 21 days prior to their
        circumcision visit:

          1. Clinically eligible for either forceps guided, or dorsal slit circumcision

          2. The ability to understand and sign a written informed consent form by participant (and
             participant's legal guardian if younger than 18 years) prior to participation in any
             study procedures and to comply with all trial requirements

          3. Male sex at birth

          4. Age 13- 24 years

          5. Haemoglobin &gt;9g/dL

          6. Weight &gt;35Kg

          7. Two negative rapid HIV antibody tests results (manufactured by different companies),
             dating from 21 days or less prior to VMMC

          8. Two locator information details (including physical address, telephone contacts,
             email) for contacting of either patient or their parent

        Exclusion Criteria:

          1. Any significant acute or chronic medical illness and current therapy that in the
             opinion of the site investigator would preclude receipt either of investigational
             products, or VMMC

          2. Any evidence that participant is not suitable for VMMC
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male genital anatomical features.</gender_description>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil A Martinson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Perinatal HIV Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neil A Martinson</last_name>
    <phone>+27 11 989 9836</phone>
    <email>martinson@phru.co.za</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Perinatal HIV Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil A Martinson</last_name>
      <phone>+27 11 989 9836</phone>
      <email>martinson@phru.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Fatima Mayat</last_name>
      <phone>+27 11 989 9798</phone>
      <email>mayatf@phru.co.za</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wits Health Consortium (Pty) Ltd</investigator_affiliation>
    <investigator_full_name>Fatima Mayat</investigator_full_name>
    <investigator_title>Professor Neil Martinson</investigator_title>
  </responsible_party>
  <keyword>Pre-exposure prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be shared with callaborators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

